Home » AMITIZA, THE FIRST SELECTIVE CHLORIDE CHANNEL ACTIVATOR FOR THE TREATMENT OF CHRONIC IDIOPATHIC CONSTIPATION
AMITIZA, THE FIRST SELECTIVE CHLORIDE CHANNEL ACTIVATOR FOR THE TREATMENT OF CHRONIC IDIOPATHIC CONSTIPATION
April 25, 2006
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals
North America, Inc., announced today that AMITIZA (lubiprostone), 24-mcg soft-gel
capsules, approved by the U.S. Food and Drug Administration (FDA) in January 2006,
is now available by prescription in pharmacies across the United States for the
treatment of chronic idiopathic constipation in adults.
Market
Wire
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct